MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer's Disease and Dementia
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
Market One Minute Feature on BNN Bloomberg: Omega Pacific Resources Drills to Expand Gold Discovery in BC's Toodoggone
QIMC Engages Global Seismic Processing Leader Earth Signal to Advance Nova Scotia Hydrogen and Helium Multi-Gas Pilot Production Pathway
